Roles for TGF-β and Programmed Cell Death 1 Ligand 1 in Regulatory T Cell Expansion and Diabetes Suppression by Zymosan in Nonobese Diabetic Mice

被引:25
|
作者
Burton, Oliver T. [1 ]
Zaccone, Paola [1 ]
Phillips, Jenny M. [1 ]
De La Pena, Hugo [1 ,2 ]
Fehervari, Zoltan [1 ]
Azuma, Miyuki [3 ]
Gibbs, Sarah [1 ]
Stockinger, Brigitta [2 ]
Cooke, Anne [1 ]
机构
[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England
[2] Natl Inst Med Res, MRC, Dept Mol Immunol, London NW7 1AA, England
[3] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
来源
JOURNAL OF IMMUNOLOGY | 2010年 / 185卷 / 05期
基金
英国惠康基金; 英国生物技术与生命科学研究理事会;
关键词
PLASMACYTOID DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; NOD MICE; EXTRACELLULAR-MATRIX; RECEPTOR DECTIN-1; CANDIDA-ALBICANS; B-LYMPHOCYTES; IN-VIVO; INDUCTION; PREVENTS;
D O I
10.4049/jimmunol.1001365
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Zymosan is a complex fungal component shown to be capable of both promoting and suppressing the development of autoimmune disorders in mice. In this study, we show that a single injection of zymosan just prior to diabetes onset can significantly delay the progression of disease in NOD mice. Zymosan treatment of NOD mice induced the production of biologically active TGF-beta from cells infiltrating the pancreas and was associated with expansion of programmed cell death 1 ligand 1(+)TGF-beta(+) macrophages and Foxp3(+) regulatory T cells in vivo. Neutralization of either TGF-beta or programmed cell death 1 ligand 1 abrogated the protective effects of zymosan. Zymosan acted through TLR2 as well as ERK and p38 MAPK to induce macrophage secretion of TGF-beta and promotion of Foxp3(+) regulatory T cells in vitro and in vivo. The Journal of Immunology, 2010, 185: 2754-2762.
引用
收藏
页码:2754 / 2762
页数:9
相关论文
共 50 条
  • [41] Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
    Jaafar, Jaafar
    Fernandez, Eugenio
    Alwan, Heba
    Philippe, Jacques
    ENDOCRINE CONNECTIONS, 2018, 7 (05): : R196 - R211
  • [42] Programmed Cell Death Ligand 1 Expression in Osteosarcoma
    Shen, Jacson K.
    Cote, Gregory M.
    Choy, Edwin
    Yang, Pei
    Harmon, David
    Schwab, Joseph
    Nielsen, G. Petur
    Chebib, Ivan
    Ferrone, Soldano
    Wang, Xinhui
    Wang, Yangyang
    Mankin, Henry
    Hornicek, Francis J.
    Duan, Zhenfeng
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (07) : 690 - 698
  • [43] Human placenta-derived mesenchymal stem cells ameliorate diabetic kidney disease by modulating the T helper 17 cell/regulatory T-cell balance through the programmed death 1/programmed death-ligand 1 pathway
    Wang, Jiao
    Liu, Honghong
    Yue, Guanru
    Deng, Yuanyuan
    Cai, Wei
    Xu, Jixiong
    DIABETES OBESITY & METABOLISM, 2024, 26 (01): : 32 - 45
  • [44] T-CELL VACCINATION AGAINST AUTOIMMUNE DIABETES IN NONOBESE DIABETIC MICE
    FORMBY, B
    SHAO, T
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1993, 23 (02): : 137 - 147
  • [45] T-CELL RECEPTOR SPECIFICITY AND DIABETES IN NONOBESE DIABETIC MICE - REPLY
    LIPES, MA
    ROSENZWEIG, A
    TAN, KN
    TANIGAWA, G
    SEIDMAN, JG
    EISENBARTH, GS
    SCIENCE, 1993, 262 (5139) : 1584 - 1584
  • [46] PROGRAMMED CELL DEATH-1 INTERACTION WITH PROGRAMMED CELL DEATH LIGAND REGULATES NEURONAL CELL DEATH IN THE MOUSE RETINA
    Gandhi, N. M.
    Sham, C.
    Chen, L.
    Yang, X.
    Sharpe, A. H.
    Freeman, G.
    Braun, J.
    Gordon, L.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 237 - 237
  • [47] Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study
    Du, Jiya
    Zhang, Qian
    Tian, Le
    Chen, Yishan
    Tian, Ye
    Dempke, Wolfram C. M.
    Arasanz, Hugo
    Soo, Ross Andrew
    Zhou, Zhiguo
    Meng, Qingju
    Liu, Yibing
    JOURNAL OF THORACIC DISEASE, 2024, 16 (12) : 8669 - 8683
  • [48] Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer
    Funaki, Soichiro
    Shintani, Yasushi
    Kawamura, Tomohiro
    Kanzaki, Ryu
    Minami, Masato
    Okumura, Meinoshin
    ONCOLOGY REPORTS, 2017, 38 (04) : 2277 - 2284
  • [49] A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
    Gaule, Patricia
    Smithy, James W.
    Toki, Maria
    Rehman, Jamaal
    Patell-Socha, Farah
    Cougot, Delphine
    Collin, Philippe
    Morrill, Paul
    Neumeister, Veronique
    Rimm, David L.
    JAMA ONCOLOGY, 2017, 3 (02) : 256 - 259
  • [50] Programmed cell death 1 ligand 1 signals in cancer cells
    Kornepati, Anand V. R.
    Vadlamudi, Ratna K.
    Curie, TylerJ
    NATURE REVIEWS CANCER, 2022, 22 (03) : 174 - 189